Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is poised for success due to its development of radiopharmaceuticals for cancer management, with its current primary revenue source being the US sales of Illuccix for prostate cancer imaging. The company utilizes a DCF valuation methodology with a probability of approval for its various programs and a sum-of-parts valuation, resulting in a total market value of $6.66B and a 12-month price objective of $20 per share. Risks include clinical and regulatory failures, delays in advancing pipelines, and competitive risks, but we reiterate our OUTPERFORM rating and maintain a $22 PT.

Bears say

Telix Pharmaceuticals is facing a negative outlook as the company largely relies on one product, Illuccix, for its revenue and has a limited current pipeline. Additionally, their main revenue source, Illuccix, is primarily used as an imaging agent and not for treating tumors, which may limit potential for future growth. The company's valuation also raises concerns, as its sum-of-parts valuation relies on a high multiple and discounted back earnings.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.